

Blueberry Therapeutics (Blueberry) today announced that it has launched a collaboration with the University of Manchester exploring the mode of action and therapeutic potential of novel anti-inflammatory agents. This collaborative project brings together leading academics at the University of Manchester with Blueberry's drug discovery and development expertise and will explore the feasibility of new approaches for the treatment of skin disorders like atopic dermatitis, psoriasis and acne. The collaboration is supported through a BBSRC Sparking Impact award made to the University of Manchester.

David Cook, Chief Scientific Officer at Blueberry Therapeutics said, "We are really excited about this collaboration with the University of Manchester. We believe that there is large unmet medical need in many skin disorders, particularly in mild to moderate disease where patients are very poorly served by current therapies, and working with Professor Kimber, Dr Dearman and their team we can explore some truly novel approaches that could ultimately benefit these patient populations. "

Professor Ian Kimber, Professor of Toxicology at the University of Manchester said that he and his colleagues were delighted with the opportunity to work with Blueberry Therapeutics and to explore jointly exciting new strategies for the treatment of inflammatory skin diseases.

ENDS

NOTES TO EDITORS

About Blueberry Therapeutics

Blueberry Therapeutics is an innovation driven Biopharmaceutical Company whose ambition is to take new therapeutic approaches that meet unmet medical needs in inflammatory and infection-associated conditions. Blueberry focuses on preclinical research through to clinical proof of concept in both humans and companion animals eventually resulting in positive clinical proof of concepts, which will be partnered with large or medium sized pharmaceutical companies for Phase III and marketing. Currently Blueberry has six key areas of research and development: bacterial Multi-Drug Resistant infections, Atopic Dermatitis, Inflammatory Bowel Disease, Onychomycosis, Tinea Pedis and acute wound care. For more information please visit: www.blueberrytherapeutics.com